ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
-
Views:
6076 -
Likes:
7
-
Views:
6076 -
Likes:
7
-
Up Next
-
5m 53s
-
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
-
5m 21sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF
-
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
5m 44s
-
8m 2s
-
33m 36sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
22m 4sPart 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s
-
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
-
17m 7sPart 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
-
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
1m 17sPart 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
1m 22sPart 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
5m 29s
-
1m 21sPart 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
3m 33s
-
31sPart 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
1m 33sPart 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
16m 12sPart 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
-
16m 24sPart 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
-
14m 3sPart 1 | Session 3 The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Amrita Mukhopadhyay, Harriette Van Spall
-
17m 32sPart 1 | Session 4 The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Christopher B Granger, Harriette Van Spall, Neha Pagidipati
-
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Roberto Diletti, Harriette Van Spall
-
5m 59sPart 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial Marielle Scherrer-Crosbie
-
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI Joo-Yong Hahn
-
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study Annapoorna Kini
-
5m 41sPart 2 | Session 4 Mini-Thoracotomy Vs Sternoctomy for Degenerative Valve Disease: The UK Mini-Mitral Study Enoch Akowuah
Overview
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the Evolut Low-Risk Trial (Medtronic Cardiovascular). This study aimed to compare transcatheter aortic valve replacement (TAVR) using Medtronic's TAVR valve with surgical aortic valve replacement (SAVR) in over 2000 patients with aortic stenosis who had low surgical risk.
TAVR had consistent benefit at 3 years compared with surgery in terms of all-cause mortality and disabling stroke.
Questions:
- What is the reasoning behind this trial?
- Please outline the patient population and study design.
- What are the main results?
- What are the implications of these findings for clinical practice?
- What further research is required?
Recorded on-site at ACC.23, New Orleans, 2023.
Comments